EyePoint Pharmaceuticals/EYPT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.

Ticker

EYPT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jay Duker

Employees

121

Headquarters

Watertown, United States

EYPT Metrics

BasicAdvanced
$558M
Market cap
-
P/E ratio
-$1.83
EPS
1.60
Beta
-
Dividend rate
$558M
1.60271
$30.99
$5.67
1.1M
5.077
5.009
-32.62%
-48.07%
-40.06%
11.152
2.138
2.232
25.70%
33.37%
10.15%

What the Analysts think about EYPT

Analyst Ratings

Majority rating from 11 analysts.
Buy

EYPT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-251.72% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$12M
-17.14%
Net income
-$29M
108.57%
Profit margin
-251.72%
151.72%

EYPT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 32.21%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.61
-$0.33
-$0.33
-$0.55
-
Expected
$0.60
-$0.51
-$0.49
-$0.42
-$0.52
Surprise
-201.88%
-35.65%
-32.11%
32.21%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for EyePoint Pharmaceuticals stock?

EyePoint Pharmaceuticals (EYPT) has a market cap of $558M as of June 17, 2024.

What is the P/E ratio for EyePoint Pharmaceuticals stock?

The price to earnings (P/E) ratio for EyePoint Pharmaceuticals (EYPT) stock is 0 as of June 17, 2024.

Does EyePoint Pharmaceuticals stock pay dividends?

No, EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next EyePoint Pharmaceuticals dividend payment date?

EyePoint Pharmaceuticals (EYPT) stock does not pay dividends to its shareholders.

What is the beta indicator for EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals (EYPT) has a beta rating of 1.6. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the EyePoint Pharmaceuticals stock price target?

The target price for EyePoint Pharmaceuticals (EYPT) stock is $40.44, which is NaN% below the current price of $. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell EyePoint Pharmaceuticals stock

Buy or sell EyePoint Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing